Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and electroCore (NASDAQ:ECOR – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.
Insider and Institutional Ownership
26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 26.7% of electroCore shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by insiders. Comparatively, 7.8% of electroCore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Vivos Therapeutics and electroCore’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
| electroCore | -39.96% | N/A | -81.35% |
Volatility & Risk
Vivos Therapeutics has a beta of 6.37, indicating that its stock price is 537% more volatile than the S&P 500. Comparatively, electroCore has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Vivos Therapeutics and electroCore, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
Vivos Therapeutics presently has a consensus target price of $2.80, indicating a potential upside of 2,888.26%. electroCore has a consensus target price of $18.00, indicating a potential upside of 148.28%. Given Vivos Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than electroCore.
Valuation & Earnings
This table compares Vivos Therapeutics and electroCore”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $17.44 million | 0.07 | -$21.17 million | ($1.90) | -0.05 |
| electroCore | $32.03 million | 2.04 | -$13.97 million | ($1.66) | -4.37 |
electroCore has higher revenue and earnings than Vivos Therapeutics. electroCore is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
electroCore beats Vivos Therapeutics on 9 of the 14 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
About electroCore
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
